Towards personalised medicine in lung and thymus neuroendocrine tumours

Affiliations

¹ Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Inter-hospital Pathology Division, Science & Technology Park, IRCCS MultiMedica, Via Gaudenzio Fantoli 16/15, 20138 Milan, Italy. Electronic address: giuseppe.pelosi@unimi.it.
² Department of Medical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
³ Department of Medical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK; CRUK and NIHR Experimental Cancer Medicine Centre and Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, UK.

Comment

Giuseppe Pelosi et al. Lancet Oncol. 2017 Dec.

. 2017 Dec;18(12):1563-1565.

doi: 10.1016/S1470-2045(17)30784-2. Epub 2017 Oct 23.

¹ Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Inter-hospital Pathology Division, Science & Technology Park, IRCCS MultiMedica, Via Gaudenzio Fantoli 16/15, 20138 Milan, Italy. Electronic address: giuseppe.pelosi@unimi.it.
² Department of Medical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
³ Department of Medical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK; CRUK and NIHR Experimental Cancer Medicine Centre and Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, UK.

No abstract available

Comment on

Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.
Ferolla P, Brizzi MP, Meyer T, Mansoor W, Mazieres J, Do Cao C, Léna H, Berruti A, Damiano V, Buikhuisen W, Grønbæk H, Lombard-Bohas C, Grohé C, Minotti V, Tiseo M, De Castro J, Reed N, Gislimberti G, Singh N, Stankovic M, Öberg K, Baudin E. Ferolla P, et al. Lancet Oncol. 2017 Dec;18(12):1652-1664. doi: 10.1016/S1470-2045(17)30681-2. Epub 2017 Oct 23. Lancet Oncol. 2017. PMID: 29074099 Clinical Trial.